Concepedia
Statistics
Publications
5
Citations
85
H-Index
Active since
2020
Affiliations
Juntendo University(Current)
National Cancer Center
Kanagawa Prefectural Hospital Organization
National Cancer Centre Japan
Tokyo National Hospital
Masahiro Torasawa is an author at Juntendo University specializing in pharmacotherapy, pembrolizumab therapy, and oncology.
Publications per year
2020–2023
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC
Ryoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita et al. · Journal of Thoracic Oncology · 2022 · 22 citations
Pharmacy, Pharmacology, Pharmacotherapy +12
Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients
Yukiko Shimoda, Ryota Shibaki, Tatsuya Yoshida et al. · Clinical Lung Cancer · 2022 · 19 citations
Life Sciences, Immunology, Oncology +14
Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy
Masahiro Torasawa, Hidehito Horinouchi, Shogo Nomura et al. · Journal of Thoracic Oncology · 2023 · 17 citations · Full text
Medicine, Oncology, Chemotherapy +15
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis
Masahiro Torasawa, Tatsuya Yoshida, Shigehiro Yagishita et al. · Lung Cancer · 2022 · 15 citations
Medicine, Oncology, Pharmacotherapy +12
Anaphylaxis to three humanized antibodies for severe asthma: a case study
Koichi Jingo, Norihiro Harada, Toshihiko Nishioki et al. · Allergy Asthma and Clinical Immunology · 2020 · 12 citations · Full text
Life Sciences, Pharmacology, Pharmacotherapy +16
1–5 of 5